Hi, Shrewd!        Login  
Shrewd'm.com 
A merry & shrewd investing community
Best Of Politics | Best Of | Favourites & Replies | All Boards | Post of the Week! | How To Invest
Search Politics
Shrewd'm.com Merry shrewd investors
Best Of Politics | Best Of | Favourites & Replies | All Boards | Post of the Week! | How To Invest
Search Politics


Halls of Shrewd'm / US Policy
Unthreaded | Threaded | Whole Thread (1) |
Author: g0177325   😊 😞
Number: of 75974 
Subject: Some good news RE Flu
Date: 02/18/26 11:36 AM
Post New | Post Reply | Report Post | Recommend It!
No. of Recommendations: 2
Perhaps the public outcry and backlash worked?

WASHINGTON — The Food and Drug Administration reversed course and told Moderna it would review its application for a new flu vaccine, the company announced Wednesday.

The agency told Moderna earlier this month that it would not review the submission because of a dispute over the design of a clinical trial, sparking an industry backlash and raising questions about broader decision-making at the FDA. The decision was made by top agency official Vinay Prasad, who STAT previously reported had overruled career scientists in the vaccine center.

Moderna is trying to secure approval for an mRNA flu vaccine for adults 50 and older. The FDA will now review the product in adults 50 to 64 through a regular pathway, and adults over 65 via accelerated approval with a requirement to run a post-marketing study. The agency will aim to review the vaccine by Aug. 5.


https://www.statnews.com/2026/02/18/fda-moderna-re...
Post New | Post Reply | Report Post | Recommend It!
Print the post
Unthreaded | Threaded | Whole Thread (1) |


Announcements
US Policy FAQ
Contact Shrewd'm
Contact the developer of these message boards.

Best Of Politics | Best Of | Favourites & Replies | All Boards | Followed Shrewds